UK biotechs T-Therapeutics and Alethio score big financings
Two up-and-coming UK biotechs – T-Therapeutics and Alethio Therapeutics – have raised $133m and $90m, respectively, in impressive financing rounds.
T-Therapeutics
Private
University of Cambridge spin-out developing next-generation T-cell receptor (TCR) therapeutics. Its OpTiMus platform generates fully human TCRs against intracellular targets, which are paired with proprietary CD3 T-cell engagers to create bispecific drugs for cancer and autoimmune disease.
Company Info
Sector:Biotechnology
Headquarters:Cambridge, England, United Kingdom
Founded:2022
Website:t-therapeutics.com/
Funding Round:Series B
Total Funding:$224M (Series A + B)
Funding & Investor Relations
Notable Investors
- Sofinnova Partners
- F-Prime Capital
- Digitalis Ventures
- Cambridge Innovation Capital
- Sanofi Ventures
- Tencent
- BGF
- University of Cambridge Venture Fund
IPO Outlook / Plans
Not disclosed
Upcoming Milestones & Key Dates
2026-11
Clinical Milestone
Advance two TCR-CD3 bispecific candidates into clinical trials with Series B proceeds
Recent News
Leadership Team
Theodora Harold
Chief Executive Officer
Allan Bradley
Founder and Chief Scientific Officer